DavidRMinorMD

Oncology • San Francisco, CA

Assistant Clinical Professor of Medicine, UCSF

Join to view full profile

Dr. Minor is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Minor's full profile

Already have an account?

Office
2200 Webster St
#511
San Francisco, CA 94115

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1976 - 1978
California Pacific Medical CenterResidency, Internal Medicine, 1974 - 1976
University of California San Francisco School of MedicineClass of 1974

Certifications & Licensure

CA State Medical License 1975 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Clinical Trial of Sutent to Treat Metastatic Melanoma Start of enrollment: 2007 Sep 01
Completed
Phase 2
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases Start of enrollment: 2016 Oct 10
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas.
David R Minor, Kevin B Kim, R Krishna M Karuturi, Mohammed Kashani-Sabet
Frontiers in Oncology. 2023-01-01
8 citations
A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.
David R Minor, Kevin B Kim, Ricky T Tong, Max C Wu, Mohammed Kashani-Sabet
Cancer Biotherapy & Radiopharmaceuticals. 2022-02-01
13 citations
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Ahmad A. Tarhini, Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen
Journal for Immunotherapy of Cancer. 2021-05-01

Press Mentions

Promising New Drug Could Help Patients Battling Deadly and Difficult to Treat Form of MelanomaMarch 8th, 2012